Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Primary Mode of Action Is A Primary Focus Of Combo Products Hearing

This article was originally published in The Gray Sheet

Executive Summary

FDA's recent announcement that it is reconsidering jurisdiction for wound products indicates a problematic shift in the agency's interpretation of "primary mode of action," AdvaMed maintained at a June 24 public hearing to discuss the regulation of combination products containing live cellular components

You may also be interested in...



FDA Will Accept Primary Mode Of Action Definition Comments Until Jan. 24

Clarification of primary mode of action (PMOA) is a priority for the soon-to-be established Office of Combination Products, according to Mark Kramer, director of the agency's current combination product program within the FDA Office of the Ombudsman

FDA Will Accept Primary Mode Of Action Definition Comments Until Jan. 24

Clarification of primary mode of action (PMOA) is a priority for the soon-to-be established Office of Combination Products, according to Mark Kramer, director of the agency's current combination product program within the FDA Office of the Ombudsman

MDUFMA Addresses In Vitro Diagnostics, Combination Product Regulation

FDA will be required to report to Congress on Center for Biologics Evaluation & Research review times for in vitro diagnostics under the "Medical Device User Fee and Modernization Act" of 2002 (MDUFMA), which cleared the House Energy & Commerce Committee Oct. 2

Related Content

UsernamePublicRestriction

Register

MT016808

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel